Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gufic Biosciences has the GF Score of 77, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Gufic Biosciences
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Gufic Biosciences GF Score Related Terms
BOM:509079 vs ZTS, UTHR: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's GF Score distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's GF Score falls into.
Gufic Biosciences (BOM:509079) has a GF Score of 77 as of Jul. 18, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Gufic Biosciences and its competitors. This is 17% below median its historical median of 93.00. Over the past decade, Gufic Biosciences' GF Score has ranged from 33.00 to 100.00.
Is Gufic Biosciences' GF Score too high?
Gufic Biosciences' current GF Score of 77 is 17% below median its 10-year median of 93.00. Over the past 10 years, this metric has ranged from a low of 33.00 to a high of 100.00. Overall, Gufic Biosciences has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' GF Score compare to ZTS and UTHR?
Gufic Biosciences' GF Score of 77 can be compared against companies in the Drug Manufacturers industry. Historically, Gufic Biosciences' own GF Score has ranged from 33.00 to 100.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Gufic Biosciences and its competitors. Gufic Biosciences's current GF Score is 77, which is 17% below median its own 10-year median of 93.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹409.46, compared to a current price of ₹381.60 — trading 6.8% below its estimated fair value. The current GF Score is 77, which is 17% below median its 10-year median of 93.00. Gufic Biosciences' overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current GF Score is 77 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹381.60 is trading 6.8% below its estimated GF Value™ of ₹409.46.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
GF Score: 77 (17% below median its 10-year median of 93.00)
GF Value™: ₹409.46 vs. price of ₹381.60 (6.8% below fair value)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
77GF Score
Get the complete analysis for BOM:509079
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
